Organ-specific lymphangiectasia, arrested lymphatic sprouting, and maturation defects resulting from gene-targeting of the PI3K regulatory isoforms p85α, p55α, and p50α

Developmental Dynamics

Volumn 238, Issue 10, 2009, Pages 2670-2679

  Mouta Bellum, Carla ^a,i   Kirov, Aleksander ^a   Miceli Libby, Laura ^a,j   Mancini, Maria L ^a,e   Petrova, Tatiana V ^a,b   Liaw, Lucy ^a   Prudovsky, Igor ^a   Thorpe, Philip E ^a,c   Miura, Naoyuki ^a,d   Cantley, Lewis C ^a,e,f   Alitalo, Kari ^a,g   Fruman, David A ^a,h   Vary, Calvin P H ^a  

^a Maine Medical Center Research Institute   (United States)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e HARVARD MEDICAL SCHOOL   (United States)

^f BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^g UNIVERSITY OF HELSINKI   (Finland)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ Finnegan Henderson Farabow Garrett and Dunner LLP   (United States)

^j MASSACHUSETTS GENERAL HOSPITAL   (United States)

more..

Author keywords

Lymphangiogenesis; Phosphatidyl inositol 3 kinase

Indexed keywords

ENDOGLIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P50; PROTEIN P55; PROTEIN P85; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; VASCULOTROPIN C;

ARTICLE; BLOOD VESSEL; DIAPHRAGM; EMBRYO; GENE DELETION; GENE TARGETING; INTESTINE; LYMPH VESSEL; LYMPHANGIECTASIS; LYMPHANGIOGENESIS; MOUSE; NEWBORN; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RECEPTOR UPREGULATION; VASCULARIZATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; ANIMALS, NEWBORN; GENE TARGETING; ISOENZYMES; LYMPHANGIECTASIS; LYMPHANGIOGENESIS; LYMPHATIC VESSELS; MICE; MICE, KNOCKOUT; PROTEIN SUBUNITS; SIGNAL TRANSDUCTION;

EID: 70349306570     PISSN: 10588388     EISSN: 10970177     Source Type: Journal    
DOI: 10.1002/dvdy.22078     Document Type: Article

References (45)

1. Abid MR, Guo S, Minami T, Spokes KC, Ueki K, Skurk C, Walsh K, Aird WC. 2004. Vascular endothelial growth factor activates PI3K/Akt/forkhead signaling in endothelial cells. Arterioscler Thromb Vasc Biol 24:294-300. (Pubitemid 38197581)
2. Bernabeu C, Conley BA, Vary C. 2007. Novel biochemical pathways of endoglin in vascular cell physiology. J Cell Biochem 102:1375-1388. (Pubitemid 350223941)
3. Blanco FJ, Santibanez JF, Guerrero-Esteo M, Langa C, Vary CP, Bernabeu C. 2005. Interaction and functional interplay between endoglin and ALK-1, two components of the endothelial transforming growth factor-beta receptor complex. J Cell Physiol 204:574-584. (Pubitemid 40934653)
4. Botella LM, Sanchez-Elsner T, Sanz-Rodriguez F, Kojima S, Shimada J, Guerrero- Esteo M, Cooreman MP, Ratziu V, Langa C, Vary CP, Ramirez JR, Friedman S, Bernabeu C. 2002. Transcriptional activation of endoglin and transforming growth factor-beta signaling components by cooperative interaction between Sp1 and KLF6: their potential role in the response to vascular injury. Blood 100:4001-4010. (Pubitemid 35396866)
5. Chen D, Mauvais-Jarvis F, Bluher M, Fisher SJ, Jozsi A, Goodyear LJ, Ueki K, Kahn CR. 2004. p50alpha/p55alpha phosphoinositide 3-kinase knockout mice exhibit enhanced insulin sensitivity. Mol Cell Biol 24:320-329. (Pubitemid 38010057)
6. Conley BA, Smith JD, Guerrero-Esteo M, Bernabeu C, Vary CP. 2000. Endoglin, a TGF-beta receptor-associated protein, is expressed by smooth muscle cells in human atherosclerotic plaques. Atherosclerosis 153:323-335. (Pubitemid 32120331)
7. Deane JA, Kharas MG, Oak JS, Stiles LN, Luo J, Moore TI, Ji H, Rommel C, Cantley LC, Lane TE, Fruman DA. 2007. T-cell function is partially maintained in the absence of class IA phosphoinositide 3-kinase signaling. Blood 109:2894-2902. (Pubitemid 46482086)
8. Engelman JA, Luo J, Cantley LC. 2006. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 7:606-619. (Pubitemid 44100518)
9. Fruman DA, Bismuth G. 2009. Fine tuning the immune response with PI3K. Immunol Rev 228:253-272.
10. Fruman DA, Snapper SB, Yballe CM, Davidson L, Yu JY, Alt FW, Cantley LC. 1999. Impaired B cell development and proliferation in absence of phosphoinositide 3-kinase p85alpha. Science 283:393-397. (Pubitemid 129501102)
11. Fruman DA, Mauvais-Jarvis F, Pollard DA, Yballe CM, Brazil D, Bronson RT, Kahn CR, Cantley LC. 2000. Hypoglycaemia, liver necrosis and perinatal death in mice lacking all isoforms of phosphoinositide 3-kinase p85 alpha. Nat Genet 26:379-382. (Pubitemid 30824626)
12. Gale NW, Thurston G, Hackett SF, Renard R, Wang Q, McClain J, Martin C, Witte C, Witte MH, Jackson D, Suri C, Campochiaro PA, Wiegand SJ, Yancopoulos GD. 2002. Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1. Dev Cell 3:411-423.
13. Garcia-Echeverria C, Sellers WR. 2008. Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene 27:5511-5526.
14. Gronning LM, Cederberg A, Miura N, Enerback S, Tasken K. 2002. Insulin and TNF alpha induce expression of the forkhead transcription factor gene Foxc2 in 3T3-L1 adipocytes via PI3K and ERK 1/2-dependent pathways. Mol Endocrinol 16:873-883. (Pubitemid 34297754)
15. Gupta S, Ramjaun AR, Haiko P, Wang Y, Warne PH, Nicke B, Nye E, Stamp G, Alitalo K, Downward J. 2007. Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice. Cell 129:957-968. (Pubitemid 46802703)
16. Jeltsch M, Tammela T, Alitalo K, Wilting J. 2003. Genesis and pathogenesis of lymphatic vessels. Cell Tissue Res 314: 69-84.
17. Karkkainen MJ, Haiko P, Sainio K, Partanen J, Taipale J, Petrova TV, Jeltsch M, Jackson DG, Talikka M, Rauvala H, Betsholtz C, Alitalo K. 2004. Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat Immunol 5:74-80. (Pubitemid 38081471)
18. Kim KE, Sung HK, Koh GY. 2007. Lymphatic development in mouse small intestine. Dev Dyn 236:2020-2025.
19. Kolbjornsen O, Press CM, Landsverk T. 1994. Gastropathies in the Lundehund. I. Gastritis and gastric neoplasia associated with intestinal lymphangiectasia. Apmis 102:647-661.
20. Kubota Y, Takubo K, Shimizu T, Ohno H, Kishi K, Shibuya M, Saya H, Suda T. 2009. M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis. J Exp Med 206:1089-1102.
21. Kumar A, Hoover JL, Simmons CA, Lindner V, Shebuski RJ. 1997. Remodeling and neointimal formation in the carotid artery of normal and P-selectin-deficient mice. Circulation 96:4333-4342. (Pubitemid 28007463)
22. Lastres P, Letamendia A, Zhang H, Rius C, Almendro N, Raab U, Lopez LA, Langa C, Fabra A, Letarte M, Bernabeu C. 1996. Endoglin modulates cellular responses to TGF-beta 1. J Cell Biol 133: 1109-1121. (Pubitemid 26172515)
23. Lymboussaki A, Partanen TA, Olofsson B, Thomas-Crusells J, Fletcher CD, de Waal RM, Kaipainen A, Alitalo K. 1998. Expression of the vascular endothelial growth factor C receptor VEGFR-3 in lymphatic endothelium of the skin and in vascular tumors. Am J Pathol 153:395-403. (Pubitemid 28373651)
24. Ma X, Labinaz M, Goldstein J, Miller H, Keon WJ, Letarte M, O'Brien E. 2000. Endoglin Is overexpressed after arterial injury and is required for transforming growth factor-ss-induced inhibition of smooth muscle cell migration. Arterioscler Thromb Vasc Biol 20:2546-2552.
25. Makinen T, Veikkola T, Mustjoki S, Karpanen T, Catimel B, Nice EC, Wise L, Mercer A, Kowalski H, Kerjaschki D, Stacker SA, Achen MG, Alitalo K. 2001. Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3. EMBO J 20:4762-4773. (Pubitemid 32848629)
26. Makinen T, Adams RH, Bailey J, Lu Q, Ziemiecki A, Alitalo K, Klein R, Wilkinson GA. 2005. PDZ interaction site in ephrinB2 is required for the remodeling of lymphatic vasculature. Genes Dev 19: 397-410. (Pubitemid 40189302)
27. Mancini ML, Verdi JM, Conley BA, Nicola T, Spicer DB, Oxburgh LH, Vary CP. 2007. Endoglin is required for myogenic differentiation potential of neural crest stem cells. Dev Biol 308:520-533. (Pubitemid 47223119)
28. McAllister KA, Grogg KM, Johnson DW, Gallione CJ, Baldwin MA, Jackson CE, Helmbold EA, Markel DS, McKinnon WC, Murrell J, McCormick MK, Pericak- Vance MA, Heutink P, Oostra BA, Haitjema T, Westerman CJJ, Porteous ME, Guttmacher AE, Letarte M, Marchuk DA. 1994. Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet 8:345-351. (Pubitemid 24375599)
29. Oka M, Iwata C, Suzuki HI, Kiyono K, Morishita Y, Watabe T, Komuro A, Kano MR, Miyazono K. 2008. Inhibition of endogenous TGF-beta signaling enhances lymphangiogenesis. Blood 111:4571-4579.
30. Oliver G. 2004. Lymphatic vasculature development. Nat Rev Immunol 4:35-45.
31. Papp M, Rohlich P, Rusznyak I, Toro I. 1962. An electron microscopic study of the central lacteal in the intestinal villus of the cat. Z Zellforsch Mikrosk Anat 57: 475-486.
32. Patan S. 2004. Vasculogenesis and angiogenesis. Cancer Treat Res 117:3-32.
33. Pece-Barbara N, Cymerman U, Vera S, Marchuk DA, Letarte M. 1999. Expression analysis of four endoglin missense mutations suggests that haploinsufficiency is the predominant mechanism for hereditary hemorrhagic telangiectasia type 1. Hum Mol Genet 8:2171-2181. (Pubitemid 29525331)
34. Peters KG, Kontos CD, Lin PC, Wong AL, Rao P, Huang L, Dewhirst MW, Sankar S. 2004. Functional significance of Tie2 signaling in the adult vasculature. Recent Prog Horm Res 59:51-71.
35. Petrova TV, Karpanen T, Norrmen C, Mellor R, Tamakoshi T, Finegold D, Ferrell R, Kerjaschki D, Mortimer P, Yla-Herttuala S, Miura N, Alitalo K. 2004. Defective valves and abnormal mural cell recruitment underlie lymphatic vascular failure in lymphedema distichiasis. Nat Med 10:974-981. (Pubitemid 39273739)
36. Pudliszewski M, Pardanaud L. 2005. Vasculogenesis and angiogenesis in the mouse embryo studied using quail/ mouse chimeras. Int J Dev Biol 49:355-361. (Pubitemid 40917358)
37. Rius C, Smith JD, Almendro N, Langa C, Botella LM, Marchuk DA, Vary CP, Bernabeu C. 1998. Cloning of the promoter region of human endoglin, the target gene for hereditary hemorrhagic telangiectasia type 1. Blood 92:4677-4690. (Pubitemid 29005870)
38. Rodriguez-Niedenfuhr M, Papoutsi M, Christ B, Nicolaides KH, von Kaisenberg CS, Tomarev SI, Wilting J. 2001. Prox1 is a marker of ectodermal placodes, endodermal compartments, lymphatic endothelium and lymphangioblasts. Anat Embryol (Berl) 204:399-406. (Pubitemid 33139877)
39. Sabin FR. 1913. The origin and development of the lymphatic system. Baltimore: The Johns Hopkins Press.
40. Saharinen P, Tammela T, Karkkainen MJ, Alitalo K. 2004. Lymphatic vasculature: development, molecular regulation and role in tumor metastasis and inflammation. Trends Immunol 25:387-395. (Pubitemid 38780956)
41. Schledzewski K, Falkowski M, Moldenhauer G, Metharom P, Kzhyshkowska J, Ganss R, Demory A, Falkowska- Hansen B, Kurzen H, Ugurel S, Geginat G, Arnold B, Goerdt S. 2006. Lymphatic endothelium-specific hyaluronan receptor LYVE-1 is expressed by stabilin-1+, F4/80+, CD11b+ macrophages in malignant tumours and wound healing tissue in vivo and in bone marrow cultures in vitro: implications for the assessment of lymphangiogenesis. J Pathol 209:67-77.
42. Stephens L, Williams R, Hawkins P. 2005. Phosphoinositide 3-kinases as drug targets in cancer. Curr Opin Pharmacol 5:357-365. (Pubitemid 40932037)
43. Tang Y, Zhang D, Fallavollita L, Brodt P. 2003. Vascular endothelial growth factor C expression and lymph node metastasis are regulated by the type I insulin-like growth factor receptor. Cancer Res 63:1166-1171. (Pubitemid 36348689)
44. Ueki K, Yballe CM, Brachmann SM, Vicent D, Watt JM, Kahn CR, Cantley LC. 2002. Increased insulin sensitivity in mice lacking p85beta subunit of phosphoinositide 3-kinase. Proc Natl Acad Sci U S A 99:419-424. (Pubitemid 34060376)
45. Wang JF, Zhang X, Groopman JE. 2004. Activation of vascular endothelial growth factor receptor-3 and its downstream signaling promote cell survival under oxidative stress. J Biol Chem 279:27088-27097. (Pubitemid 38812545)